Subscribe to RSS
Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark
Objective To describe life-time use of current actionable pharmacogenetic (PGx) somatic and psychotropic drugs according to international PGx consortia in people with and without hospital-diagnosed mental disorders in the Danish population.
Methods Population- and register-based observational drug utilization study in 56 065 individuals with mental disorders, i. e. attention-deficit/hyperactivity disorder, autism, bipolar disorder, depression and schizophrenia, and a random, representative sample of 29 975 individuals of the Danish population, born between 1981 and 2005. Individuals were followed from 1995 or birth until 2016 (for a maximum of 22 years). We report prevalence and incidence rates of PGx drug use by age, sex and mental disorders based on redeemed prescriptions between 1995 and 2016.
Results Of the 69 PGx drugs, prescriptions of 39 drugs had been redeemed by the study population by 35 years of age. The use of at least 1 PGx drug varied between 23.1% in males without mental disorders and 97.2% in females with schizophrenia. Males with ADHD or autism were the youngest first-time PGx drug users at a mean of 11.6 years. The mean number of different PGx drugs used was 1.2 in males without mental disorders and 5.6 in individuals with schizophrenia. The prevalence of different PGx drugs linked to more than one gene was 25.3% in males without mental disorders to 94.1% in females with schizophrenia.
Conclusion PGx drugs are commonly used by younger people, more often by individuals with mental disorders and by females. Panel-based PGx testing could contribute to treatment decisions at a very young age.
Received: 19 April 2021
Received: 31 August 2021
Accepted: 08 September 2021
Article published online:
09 November 2021
© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Weinshilboum RM, Wang L. Pharmacogenomics: Precision medicine and drug response. Mayo Clin Proc 2017; 92: 1711-1722 DOI: 10.1016/j.mayocp.2017.09.001.
- 2 Swen JJ, Wilting I, de Goede AL. et al. Pharmacogenetics: From bench to byte. Clin Pharmacol Ther 2008; 83: 781-787 DOI: 10.1038/sj.clpt.6100507.
- 3 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: From bench to byte--an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673 DOI: 10.1038/clpt.2011.34.
- 4 Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-467 DOI: 10.1038/clpt.2010.279.
- 5 Lunenburg CATC, Gasse C. Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Res 2020; 292: 113336 DOI: 10.1016/j.psychres.2020.113336.
- 6 Stern S, Linker S, Vadodaria KC. et al. Prediction of response to drug therapy in psychiatric disorders. Open Biol 2018; 8. doi:10.1098/rsob.180031
- 7 Hahn M, Müller DJ, Roll SC. Frequencies of genetic polymorphisms of clinically relevant gene-drug pairs in a German psychiatric inpatient population. Pharmacopsychiatry 2020. doi:10.1055/a-1312-7175
- 8 Henricks LM, Lunenburg CATC, de Man FM. et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis. Lancet Oncol 2018; 19: 1459-1467 DOI: 10.1016/S1470-2045(18)30686-7.
- 9 Bousman CA, Bengesser SA, Aitchison KJ. et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 2021; 54: 5-17 DOI: 10.1055/a-1288-1061.
- 10 Youssef E, Kirkdale CL, Wright DJ. et al. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br J Clin Pharmacol 2021; 87: 2907-2925 DOI: 10.1111/bcp.14704.
- 11 Samwald M, Xu H, Blagec K. et al. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One 2016; 11: e0164972 DOI: 10.1371/journal.pone.0164972.
- 12 Bank PCD, Swen JJ, Guchelaar HJ. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Med 2019; 17: 110 DOI: 10.1186/s12916-019-1342-5.
- 13 Alshabeeb MA, Deneer VHM, Khan A. et al. Use of pharmacogenetic drugs by the Dutch population. Front Genet 2019; 10: 567 DOI: 10.3389/fgene.2019.00567.
- 14 Lunenburg C, Hauser A, Ishtiak-Ahmed K. et al. Primary care prescription drug use and related actionable drug-gene interactions in the Danish population. Clin Transl Sci 2020; 13: 798-806 DOI: 10.1111/cts.12768.
- 15 Westergaard N, Sogaard Nielsen R, Jorgensen S. et al. Drug use in Denmark for drugs having pharmacogenomics (PGx) based dosing guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 drug-gene pairs: Perspectives for introducing PGx test to polypharmacy patients. J Pers Med 2020; 10. doi:10.3390/jpm10010003
- 16 Benitez J, Jablonski MR, Allen JD. et al. The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes. Appl Transl genomics 2015; 5: 47-49 DOI: 10.1016/j.atg.2015.03.001.
- 17 Brown L, Vranjkovic O, Li J. et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics 2020; 21: 559-569 DOI: 10.2217/pgs-2019-0157.
- 18 Bousman C, Maruf AAl, Muller DJ. Towards the integration of pharmacogenetics in psychiatry: A minimum, evidence-based genetic testing panel. Curr Opin Psychiatry 2019; 32: 7-15 DOI: 10.1097/YCO.0000000000000465.
- 19 Pedersen CB, Bybjerg-Grauholm J, Pedersen MG. et al. The iPSYCH2012 case-cohort sample: New directions for unravelling genetic and environmental architectures of severe mental disorders. Mol Psychiatry 2018; 23: 6-14 DOI: 10.1038/mp.2017.196.
- 20 Pedersen CB. The Danish civil registration system. Scand J Public Health 2011; 39: 22-25 DOI: 10.1177/1403494810387965.
- 21 Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39: 38-41 DOI: 10.1177/1403494810394717.
- 22 Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-33 DOI: 10.1177/1403494811401482.
- 23 Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health 2011; 39: 54-57 DOI: 10.1177/1403494810395825.
- 24 Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39: 26-29 DOI: 10.1177/1403494811399958.
- 25 Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines. Last Update 04-06-2020
- 26 KNMP (Royal Dutch Pharmacists Association). Pharmacogenetic Recommendations. Last Update May 2020
- 27 Carstensen B, Dickman P. Lexis macro for splitting follow-up. 2003: http://bendixcarstensen/Lexis/Lexis.sas
- 28 Kimpton JE, Carey IM, Threapleton CJD. et al. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Pharmacol 2019; 85: 2734-2746 DOI: 10.1111/bcp.14100.
- 29 Hicks JK, El Rouby N, Ong HH. et al. Opportunity for genotype-guided prescribing among adult patients in 11 U.S. health systems. Clin Pharmacol Ther 2021; 110: 179-188 DOI: 10.1002/cpt.2161.
- 30 Ramsey LB, Ong HH, Schildcrout JS. et al. Prescribing prevalence of medications with potential genotype-guided dosing in pediatric patients. JAMA Netw open 2020; 3: e2029411 DOI: 10.1001/jamanetworkopen.2020.29411.
- 31 Lunenburg CATC, Thirstrup JP, Bybjerg-Grauholm J. et al. Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Transl Psychiatry 2021; 11: 294 DOI: 10.1038/s41398-021-01417-4.
- 32 McDaid A, Logette E, Buchillier V. et al. Risk prediction of developing venous thrombosis in combined oral contraceptive users. PLoS One 2017; 12: e0182041 DOI: 10.1371/journal.pone.0182041.
- 33 Dickerson F, Schroeder J, Katsafanas E. et al. Cigarette smoking by patients with serious mental illness, 1999-2016: An increasing disparity. Psychiatr Serv 2018; 69: 147-153 DOI: 10.1176/appi.ps.201700118.
- 34 Köhler-Forsberg O, Petersen L, Ishtiak-Ahmed K. et al. Medical diseases prior to first-time depression diagnosis and subsequent risk of admissions for depression: A nationwide study of 117,585 patients. J Affect Disord 2020; 276: 1030-1037 DOI: 10.1016/j.jad.2020.07.057.
- 35 Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One 2011; 6: e24597 DOI: 10.1371/journal.pone.0024597.
- 36 Schildcrout JS, Denny JC, Bowton E. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther 2012; 92: 235-242 DOI: 10.1038/clpt.2012.66.
- 37 van der Wouden CH, Bank PCD, Ozokcu K. et al. Pharmacist-initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: Record of PGx results and real-world impact. Genes (Basel) 2019; 10. doi: 10.3390/genes10060416
- 38 Chanfreau-Coffinier C, Hull LE, Lynch JA. et al. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among US veterans health administration pharmacy users. JAMA Netw open 2019; 2: e195345 DOI: 10.1001/jamanetworkopen.2019.5345.
- 39 Vermehren C, Søgaard Nielsen R, Jørgensen S. et al. Drug use among nursing home residents in Denmark for drugs having pharmacogenomics based (PGx) dosing guidelines: Potential for preemptive PGx testing. J Pers Med 2020; 10. doi:10.3390/jpm10030078
- 40 Milosavljevic F, Bukvic N, Pavlovic Z. et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: A systematic review and meta-analysis. JAMA psychiatry 2021; 78: 270-280 DOI: 10.1001/jamapsychiatry.2020.3643.
- 41 Holm EA. In defense of the black box. Science 2019; 364: 26-27 DOI: 10.1126/science.aax0162.
- 42 Marok FZ, Fuhr LM, Hanke N. et al. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics 2021; 13. doi:10.3390/pharmaceutics13030331
- 43 Bousman CA, Eyre HA. "Black box“ pharmacogenetic decision-support tools in psychiatry. Rev Bras Psiquiatr 2020; 42: 113-115 DOI: 10.1590/1516-4446-2019-0724.
- 44 Pedersen CB, Mors O, Bertelsen A. et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014; 71: 573-581 DOI: 10.1001/jamapsychiatry.2014.16.
- 45 Dalsgaard S, Thorsteinsson E, Trabjerg BB. et al. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA psychiatry 2020; 77: 155-164 DOI: 10.1001/jamapsychiatry.2019.3523.
- 46 Lo C, Nguyen S, Yang C. et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci 2020; 13: 861-870 DOI: 10.1111/cts.12771.
- 47 Hernandez W, Danahey K, Pei X. et al. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J 2020; 20: 126-135 DOI: 10.1038/s41397-019-0095-z.